Peter M. Irving

456 total citations · 1 hit paper
12 papers, 186 citations indexed

About

Peter M. Irving is a scholar working on Genetics, Epidemiology and Surgery. According to data from OpenAlex, Peter M. Irving has authored 12 papers receiving a total of 186 indexed citations (citations by other indexed papers that have themselves been cited), including 10 papers in Genetics, 7 papers in Epidemiology and 3 papers in Surgery. Recurrent topics in Peter M. Irving's work include Inflammatory Bowel Disease (10 papers), Microscopic Colitis (6 papers) and Liver Diseases and Immunity (3 papers). Peter M. Irving is often cited by papers focused on Inflammatory Bowel Disease (10 papers), Microscopic Colitis (6 papers) and Liver Diseases and Immunity (3 papers). Peter M. Irving collaborates with scholars based in United Kingdom, United States and Italy. Peter M. Irving's co-authors include Xingyuan Li, Janelle Laskowski, Geert D’Haens, Nathan Morris, Juris Pokrotnieks, Joe Milata, William J. Sandborn, Catherine Milch, Marla C. Dubinsky and Vipin Arora and has published in prestigious journals such as New England Journal of Medicine, Gastroenterology and The American Journal of Gastroenterology.

In The Last Decade

Peter M. Irving

9 papers receiving 180 citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Mirikizumab as Induction and Maintenance Therapy for Ulcerative Colitis

2023 170 citations Geert D’Haens, Marla C. Dubinsky et al. New England Journal of Medicine profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Peter M. Irving United Kingdom	3	162	121	51	45	22	12	186
Claire Liefferinckx Belgium	8	181 1.1×	136 1.1×	83 1.6×	55 1.2×	15 0.7×	23	230
Marijana Protić United States	8	160 1.0×	138 1.1×	36 0.7×	56 1.2×	11 0.5×	33	222
Laurent Peyrin-Biroulet France	7	102 0.6×	66 0.5×	31 0.6×	41 0.9×	15 0.7×	43	151
Alexandros Skamnelos Greece	7	91 0.6×	67 0.6×	24 0.5×	54 1.2×	24 1.1×	16	154
Laura Loy Italy	8	106 0.7×	68 0.6×	49 1.0×	41 0.9×	11 0.5×	22	166
P. Hindryckx Belgium	4	94 0.6×	96 0.8×	33 0.6×	43 1.0×	6 0.3×	4	152
Luisa de Castro Spain	6	160 1.0×	133 1.1×	25 0.5×	54 1.2×	9 0.4×	9	176
Edouard Louis Belgium	6	205 1.3×	152 1.3×	88 1.7×	68 1.5×	42 1.9×	21	268
Michael Sprakes United Kingdom	6	165 1.0×	131 1.1×	67 1.3×	67 1.5×	16 0.7×	7	216
Laura Cantoro Italy	8	113 0.7×	88 0.7×	26 0.5×	76 1.7×	26 1.2×	10	178

Countries citing papers authored by Peter M. Irving

Since Specialization

Citations

This map shows the geographic impact of Peter M. Irving's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Peter M. Irving with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Peter M. Irving more than expected).

Fields of papers citing papers by Peter M. Irving

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Peter M. Irving. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Peter M. Irving. The network helps show where Peter M. Irving may publish in the future.

Co-authorship network of co-authors of Peter M. Irving

This figure shows the co-authorship network connecting the top 25 collaborators of Peter M. Irving. A scholar is included among the top collaborators of Peter M. Irving based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Peter M. Irving. Peter M. Irving is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

12 of 12 papers shown

Panaccione, Remo, Marc Ferrante, Iris Dotan, et al.. (2025). Extended Risankizumab Treatment in Patients With Crohn’s Disease Who Did Not Achieve Clinical Response to Induction Treatment. Clinical Gastroenterology and Hepatology. 23(11). 2012–2022.e6. 3 indexed citations

Bancil, Aaron, Alicia Sandall, Selina Cox, et al.. (2025). 796: A MULTI-CENTRE, RANDOMISED, DOUBLE-BLIND, PLACEBO-CONTROLLED, RE-SUPPLEMENTATION TRIAL DEMONSTRATES THE EFFICACY OF A LOW EMULSIFIER DIET IN 154 PATIENTS WITH MILD TO MODERATELY ACTIVE CROHN’S DISEASE: THE ADDAPT TRIAL. Gastroenterology. 169(1). S–187.

Lichtenstein, Gary R., Jessica R. Allegretti, Edward V. Loftus, et al.. (2025). Assessment and Impact of Age on the Safety and Efficacy of Etrasimod in Patients With Ulcerative Colitis: A Post Hoc Analysis of Data From the ELEVATE UC Clinical Program. Inflammatory Bowel Diseases. 31(9). 2352–2362. 1 indexed citations

Vermeire, Séverine, David T. Rubin, Laurent Peyrin‐Biroulet, et al.. (2023). S905 Impact of Etrasimod on Blood Pressure and Hypertension: Data From the Etrasimod Ulcerative Colitis Clinical Program. The American Journal of Gastroenterology. 118(10S). S675–S675.

D’Haens, Geert, Marla C. Dubinsky, Taku Kobayashi, et al.. (2023). Mirikizumab as Induction and Maintenance Therapy for Ulcerative Colitis. New England Journal of Medicine. 388(26). 2444–2455. 170 indexed citations breakdown →

Dubinsky, Marla C., Séverine Vermeire, María Chaparro, et al.. (2023). S843 Symptomatic Improvement Observed Within 2 Days of Etrasimod Induction Therapy: Results From ELEVATE UC 52 and ELEVATE UC 12 Studies in Patients With Ulcerative Colitis. The American Journal of Gastroenterology. 118(10S). S623–S623.

Panaccione, Remo, Bruce E. Sands, Silvio Danese, et al.. (2022). Tu1445: EFFECT OF PHARMACOKINETICS AND IMMUNOGENICITY ON CLINICAL AND ENDOSCOPIC EFFICACY IN PATIENTS WITH MODERATELY-TO-SEVERELY ACTIVE CROHN'S DISEASE: RESULTS FROM THE SEAVUE STUDY. Gastroenterology. 162(7). S–963. 1 indexed citations

Lewis, James D., Matthieu Allez, Stephen B. Hanauer, et al.. (2022). Su1513: IMPACT OF MODERATE-TO-SEVERE ENDOSCOPIC DISEASE CRITERIA ON ENDOSCOPIC RESPONSE, ENDOSCOPIC REMISSION, AND DEEP REMISSION IN PATIENTS RECEIVING USTEKINUMAB OR ADALIMUMAB IN THE SEAVUE STUDY. Gastroenterology. 162(7). S–608. 1 indexed citations

Sands, Bruce E., Remo Panaccione, Christopher Gasink, et al.. (2022). Mo1479: PERIANAL FISTULA CLOSURE IN PATIENTS RECEIVING USTEKINUMAB: RESULTS FROM THE SEAVUE AND STARDUST TRIALS. Gastroenterology. 162(7). S–782. 1 indexed citations

10.

Dubinsky, Marla C., Peter M. Irving, Xingyuan Li, et al.. (2022). 867e: EFFICACY AND SAFETY OF MIRIKIZUMAB AS MAINTENANCE THERAPY IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS: RESULTS FROM THE PHASE 3 LUCENT-2 STUDY. Gastroenterology. 162(7). S–1393. 7 indexed citations

11.

Lewis, James D., Matthieu Allez, Peter M. Irving, et al.. (2021). S851 Health-Related Quality of Life With Ustekinumab vs Adalimumab for Induction and Maintenance Therapy in Biologic-Naïve Patients With Moderate-To-Severe Crohn’s Disease: PROMIS-29 in the SEAVUE Study. The American Journal of Gastroenterology. 116(1). S395–S395. 1 indexed citations

12.

Honap, Sailish, Thomas Chapman, Desmond Chee, et al.. (2020). Tu1893 REAL WORLD EFFECTIVENESS OF TOFACITINIB FOR MODERATE TO SEVERE ULCERATIVE COLITIS: A MULTI-CENTRE UK EXPERIENCE. Gastroenterology. 158(6). S–1207. 1 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact